Cargando…

Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials

BACKGROUND: To facilitate translational drug development for liver fibrosis, preclinical trials need to be run in parallel with clinical research. Liver function estimation by gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) is being established in clinical research, but still rarely used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huh, Jimi, Ham, Su Jung, Cho, Young Chul, Park, Bumwoo, Kim, Bohyun, Woo, Chul-Woong, Choi, Yoonseok, Woo, Dong-Cheol, Kim, Kyung Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858707/ https://www.ncbi.nlm.nih.gov/pubmed/31729971 http://dx.doi.org/10.1186/s12880-019-0378-5

Ejemplares similares

Test-retest repeatability of ultrasonographic shear wave elastography in a rat liver fibrosis model: toward a quantitative biomarker for preclinical trials
por: Shin, Youngbin, et al.
Publicado: (2021)

Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver
por: Huh, Jimi, et al.
Publicado: (2015)

Deep Learning-Based Assessment of Functional Liver Capacity Using Gadoxetic Acid-Enhanced Hepatobiliary Phase MRI
por: Park, Hyo Jung, et al.
Publicado: (2022)

Benign nodules mimicking hepatocellular carcinoma on gadoxetic acid-enhanced liver MRI
por: Song, Kyoung Doo, et al.
Publicado: (2015)

Prediction of Decompensation and Death in Advanced Chronic Liver Disease Using Deep Learning Analysis of Gadoxetic Acid-Enhanced MRI
por: Heo, Subin, et al.
Publicado: (2022)

Quantification of liver function using gadoxetic acid-enhanced MRI
por: Poetter-Lang, Sarah, et al.
Publicado: (2020)

Comparison of Dynamic and Liver-Specific Gadoxetic Acid Contrast-Enhanced MRI versus Apparent Diffusion Coefficients
por: Morelli, John N., et al.
Publicado: (2013)

Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI
por: Kim, Seung Hyun, et al.
Publicado: (2013)

Histogram Analysis of Gadoxetic Acid-Enhanced MRI for Quantitative Hepatic Fibrosis Measurement
por: Kim, Honsoul, et al.
Publicado: (2014)

Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI
por: Youn, Seo Yeon, et al.
Publicado: (2021)

Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI
por: van Kessel, C. S., et al.
Publicado: (2012)

Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects
por: Chae, Yeon Ji, et al.
Publicado: (2022)

Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases
por: Cheung, Helen M. C., et al.
Publicado: (2018)

Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure
por: Zhu, Wang-Shu, et al.
Publicado: (2020)

Differentiating Focal Eosinophilic Infiltration from Metastasis in the Liver with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging
por: Lee, Mi Hee, et al.
Publicado: (2011)

Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma
por: Jin, Young-Joo, et al.
Publicado: (2017)

Gadoxetic Acid-Enhanced MRI and Sonoelastography: Non-Invasive Assessments of Chemoprevention of Liver Fibrosis in Thioacetamide-Induced Rats with Sho-Saiko-To
por: Chen, Ya-Wen, et al.
Publicado: (2014)

Relative Enhancement in Gadoxetate Disodium-Enhanced Liver MRI as an Imaging Biomarker in the Diagnosis of Non-Alcoholic Fatty Liver Disease in Pediatric Obesity
por: Hojreh, Azadeh, et al.
Publicado: (2023)

Predictive value of gadoxetic acid–enhanced MRI for posthepatectomy liver failure: a systematic review
por: Wang, Qiang, et al.
Publicado: (2021)

Influence of dilution on arterial-phase artifacts and signal intensity on gadoxetic acid–enhanced liver MRI
por: Poetter-Lang, Sarah, et al.
Publicado: (2022)

Influence of B(1)-Inhomogeneity on Pharmacokinetic Modeling of Dynamic Contrast-Enhanced MRI: A Simulation Study
por: Park, Bumwoo, et al.
Publicado: (2017)

Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases
por: Zech, C J, et al.
Publicado: (2014)

Increase in lesion enhancement on gadoxetic acid enhanced MRI is associated with complete response to neoadjuvant chemotherapy in colorectal liver metastases
por: Islam, S, et al.
Publicado: (2015)

A radiomics-based model to classify the etiology of liver cirrhosis using gadoxetic acid-enhanced MRI
por: Elkilany, Aboelyazid, et al.
Publicado: (2021)

Suboptimal hepatobiliary phase image in gadoxetic acid-enhanced liver MRI for the evaluation of the HCC: Predictive factors
por: Ryeom, Hunkyu, et al.
Publicado: (2023)

Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
por: Öcal, Osman, et al.
Publicado: (2021)

Diagnostic performance of abbreviated gadoxetic acid-enhanced magnetic resonance protocols with contrast-enhanced computed tomography for detection of colorectal liver metastases
por: Ozaki, Kumi, et al.
Publicado: (2022)

MR Imaging in Patients with Suspected Liver Metastases: Value of Liver-Specific Contrast Agent Gadoxetic Acid
por: Lee, Kyung Hee, et al.
Publicado: (2013)

Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation
por: Odedra, Devang, et al.
Publicado: (2022)

Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging
por: Kim, Yeun-Yoon, et al.
Publicado: (2022)

Aberrant expression of OATP1B3 in colorectal cancer liver metastases and its clinical implication on gadoxetic acid-enhanced MRI
por: Park, Seung Hyun, et al.
Publicado: (2017)

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI
por: Haider, Lukas, et al.
Publicado: (2018)

Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases
por: Beer, Lucian, et al.
Publicado: (2019)

Correction of Arterial-Phase Motion Artifacts in Gadoxetic Acid-Enhanced Liver MRI Using an Innovative Unsupervised Network
por: Pan, Feng, et al.
Publicado: (2023)

Diagnostic performance of gadoxetic acid–enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection
por: Granata, Vincenza, et al.
Publicado: (2019)

Validation of 10-Minute Delayed Hepatocyte Phase Imaging with 30° Flip Angle in Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastasis
por: Lee, Dahye, et al.
Publicado: (2015)

The imaging findings of Peliosis hepatis on gadoxetic acid enhanced MRI
por: Yoshida, Morikatsu, et al.
Publicado: (2020)

The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MR imaging: Correlation with pathology and dynamic CT
por: Kim, Bohyun, et al.
Publicado: (2018)

A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function
por: Karageorgis, Anastassia, et al.
Publicado: (2018)

Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression
por: Elkilany, Aboelyazid, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0us68h09359q9nth9m445rk6sh